Get started
Author

Rana Hasen Shembesh

Observed names: R.H. Shembesh, Rana H Shembesh, Rana H. Shembesh, Rana Shembesh
Observed institution: Libyan International University
ORCID: 0000-0002-6287-6791
Observed ORCID: 0000-0002-6287-6791
OpenAlex ID: A5114640965
PD-1/PD-L1 inhibitors in advanced, unresectable esophageal squamous-cell carcinoma: A meta-analysis of their effects across patient subgroups
2025 · Mohammed S. Beshr, Rana H. Shembesh, et al. · Critical Reviews in Oncology/Hematology · 5
Nonsteroidal Anti-Inflammatory Drugs as Part of a Multimodal Postoperative Pain Management Strategy in Patients Undergoing Cardiac Surgery: A Meta-Analysis of 11 Randomized Clinical Trials
2025 · Mohammed S. Beshr, Rana H. Shembesh, et al. · Journal of Cardiothoracic and Vascular Anesthesia · 4
Immune Checkpoint Inhibitor Therapy for Advanced, Unresectable Esophageal Squamous Cell Carcinoma: A Series of Patient-level Meta-analyses From Phase III Trials
2026 · M.S. Beshr, R.H. Shembesh, et al. · Clinical Oncology · 2
Efficacy of Semaglutide and Other GLP-1 Agonists in Patients with Heart Failure With Preserved Ejection Fraction and Obesity: A Systemic Review and Meta-Analysis.
2025 · Mohammed S Beshr, Rana H Shembesh, et al. · PubMed · 2
PD-1/PD-L1 inhibitors as second-line therapy for advanced, unresected esophageal squamous-cell carcinoma: A series of patient-level meta-analyses.
2025 · Mohammed S Beshr, Mohamed E. Ali, et al. · Journal of Clinical Oncology · 1
PDF
The psychological impact of storm Daniel on medical students at the University of Derna in Libya: A cross-sectional study
2025 · Rana H. Shembesh, Mohammed S. Beshr, et al. · Cambridge Prisms Global Mental Health · 1
Xerostomia among users of electronic nicotine delivery systems in a multinational web-based cross-sectional study
2026 · Saadi M. Saleh, Hawwa Abdullah Albishari, et al. · Scientific Reports
PDF
CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials
2026 · Mohammed S Beshr, Ammar Fahaid, et al. · The Lancet Oncology
PDF
The diagnostic performance of machine learning based detection of urinary tract stones: a systematic review and meta-analysis
2026 · Mohamed Hajalamin, Ahmed Msherghi, et al. · European Journal of Radiology
Somatostatin analog therapy in delaying progression of polycystic liver disease: A meta-analysis with trial sequential analysis
2026 · Mohammed S. Beshr, Rana H. Shembesh, et al. · iLiver
Allopurinol Use Is Associated with Decreased Incidence of Hepatic Decompensation and Overall Mortality among Individuals with Cirrhosis: A Propensity-Matched Cohort Study
2025 · Mohammad Al Hayek, Bisher Sawaf, et al. · GE Portuguese Journal of Gastroenterology
PDF
128P Efficacy of fluvestrant with cyclic dependent kinase 4/6 inhibitors when used first- versus second-line in advanced breast cancer: A patient level meta-analysis
2025 · M.S. Beshr, R.H. Shembesh, et al. · Annals of Oncology
149eP Cyclic kinase 4 and 6 inhibitor plus endocrine therapy (ET) as first-line therapies in advanced breast cancer: A patient-level data network meta-analysis
2025 · M.S. Beshr, A. Fahaid, et al. · Annals of Oncology
148eP Efficacy of CDK4/6 inhibitor plus endocrine therapy (ET) based on menopausal status in advanced breast cancer: A patient level meta-analysis
2025 · M.S. Beshr, R.H. Shembesh, et al. · Annals of Oncology
141eP Selective estrogen receptor degraders (SERDs) versus non-steroidal aromatase inhibitors (NSAIs) as first-line therapy in advanced breast cancer: A patient level meta-analysis
2025 · R.H. Shembesh, M.S. Beshr, et al. · Annals of Oncology
122P Efficacy of CDK4-6 inhibitor plus endocrine therapy based on PI3K mutation status in advanced breast cancer: A patient level meta-analysis
2025 · R.H. Shembesh, M.S. Beshr, et al. · Annals of Oncology
107P Efficacy of cyclic kinase 4/6 inhibitor plus endocrine therapy based on line of therapy in advanced breast cancer: A reconstructed individual participant data meta-analysis
2025 · A. Fahaid, R.H. Shembesh, et al. · Annals of Oncology
Safety of Prophylactic Ureteral Stents in Colorectal Surgery: A Systematic Review and Meta-Analysis
2025 · Mohammed Benhammou, Ghada Kareem, et al. · The American Surgeon
Spiral enteroscopy versus single-balloon enteroscopy for the evaluation and treatment of small bowel disorders: a systematic review and meta-analysis
2025 · Bisher Sawaf, Mohammed S. Beshr, et al. · Clinical Endoscopy
PDF
S1967 Etrolizumab as Induction and Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta-Analysis
2025 · Mohammed S. Beshr, Rana H. Shembesh, et al. · The American Journal of Gastroenterology
S1968 Allogeneic Mesenchymal Stem Cells in the Treatment of Perianal Fistula in Crohn’s Disease: A Meta-Analysis
2025 · Mohammed S. Beshr, Rana H. Shembesh, et al. · The American Journal of Gastroenterology
Letter to Editor on Qureshi et al. Efficacy and Safety of Abemaciclib in Combination with Endocrine Therapy for HR+/HER2− Advanced or Metastatic Breast Cancer a Systematic Review and Meta-Analysis, Am J Clin Oncol, 2025, 48(1)
2025 · Rana H. Shembesh, Mohammed S. Beshr, et al. · American Journal of Clinical Oncology
Comparative Efficacy of IL-12/23 and IL-23 Inhibitors for Induction and Maintenance Therapy in Moderate-to-Severe Crohn’s Disease: A Systematic Review and Network Meta-Analysis
2025 · Mohammad Al Hayek, Bisher Sawaf, et al. · Inflammatory Intestinal Diseases
PDF
Evaluation of prediabetes as a potential risk factor for breast cancer: A systematic review and meta-analysis.
2025 · Rana H. Shembesh, Mohammed S. Beshr, et al. · Journal of Clinical Oncology
PDF
The addition of abemaciclib to endocrine therapy versus endocrine therapy alone in HR+/HER2− advanced breast cancer: A meta-analysis.
2025 · Mohammed S. Beshr, Rana H. Shembesh, et al. · Journal of Clinical Oncology
Works count: 40
Citation count: 15
H-index: 2
I10-index:
Year
Topic
Type